Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,416 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Single Oral Doses of MK-8507, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor, Suppress HIV-1 RNA for a Week.
Schürmann D, Jackson Rudd D, Schaeffer A, De Lepeleire I, Friedman EJ, Robberechts M, Zhang S, Liu Y, Kandala B, Keicher C, Däumer M, Hofmann J, Grobler JA, Stoch SA, Iwamoto M, Ankrom W. Schürmann D, et al. Among authors: iwamoto m. J Acquir Immune Defic Syndr. 2022 Feb 1;89(2):191-198. doi: 10.1097/QAI.0000000000002834. J Acquir Immune Defic Syndr. 2022. PMID: 34654041 Free PMC article. Clinical Trial.
Lack of a significant drug interaction between raltegravir and tenofovir.
Wenning LA, Friedman EJ, Kost JT, Breidinger SA, Stek JE, Lasseter KC, Gottesdiener KM, Chen J, Teppler H, Wagner JA, Stone JA, Iwamoto M. Wenning LA, et al. Among authors: iwamoto m. Antimicrob Agents Chemother. 2008 Sep;52(9):3253-8. doi: 10.1128/AAC.00005-08. Epub 2008 Jul 14. Antimicrob Agents Chemother. 2008. PMID: 18625763 Free PMC article. Clinical Trial.
Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.
Anderson MS, Kakuda TN, Hanley W, Miller J, Kost JT, Stoltz R, Wenning LA, Stone JA, Hoetelmans RM, Wagner JA, Iwamoto M. Anderson MS, et al. Among authors: iwamoto m. Antimicrob Agents Chemother. 2008 Dec;52(12):4228-32. doi: 10.1128/AAC.00487-08. Epub 2008 Oct 6. Antimicrob Agents Chemother. 2008. PMID: 18838586 Free PMC article. Clinical Trial.
Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics.
Iwamoto M, Hanley WD, Petry AS, Friedman EJ, Kost JT, Breidinger SA, Lasseter KC, Robson R, Lunde NM, Wenning LA, Stone JA, Wagner JA. Iwamoto M, et al. Antimicrob Agents Chemother. 2009 May;53(5):1747-52. doi: 10.1128/AAC.01194-08. Epub 2009 Feb 17. Antimicrob Agents Chemother. 2009. PMID: 19223645 Free PMC article. Clinical Trial.
Effect of low-, moderate-, and high-fat meals on raltegravir pharmacokinetics.
Brainard DM, Friedman EJ, Jin B, Breidinger SA, Tillan MD, Wenning LA, Stone JA, Chodakewitz JA, Wagner JA, Iwamoto M. Brainard DM, et al. Among authors: iwamoto m. J Clin Pharmacol. 2011 Mar;51(3):422-7. doi: 10.1177/0091270010367652. Epub 2010 May 10. J Clin Pharmacol. 2011. PMID: 20457591 Clinical Trial. No abstract available.
Characterisation of the absorption, distribution, metabolism, excretion and mass balance of doravirine, a non-nucleoside reverse transcriptase inhibitor in humans.
Sanchez RI, Fillgrove KL, Yee KL, Liang Y, Lu B, Tatavarti A, Liu R, Anderson MS, Behm MO, Fan L, Li Y, Butterton JR, Iwamoto M, Khalilieh SG. Sanchez RI, et al. Among authors: iwamoto m. Xenobiotica. 2019 Apr;49(4):422-432. doi: 10.1080/00498254.2018.1451667. Epub 2018 Mar 28. Xenobiotica. 2019. PMID: 29557716 Clinical Trial.
Severe Renal Impairment Has Minimal Impact on Doravirine Pharmacokinetics.
Ankrom W, Yee KL, Sanchez RI, Adedoyin A, Fan L, Marbury T, Preston RA, Iwamoto M, Khalilieh SG. Ankrom W, et al. Among authors: iwamoto m. Antimicrob Agents Chemother. 2018 Jul 27;62(8):e00326-18. doi: 10.1128/AAC.00326-18. Print 2018 Aug. Antimicrob Agents Chemother. 2018. PMID: 29891610 Free PMC article. Clinical Trial.
1,416 results